Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

GNE-317

GNE-317
GNE-317, a PI3K/mTOR inhibitor, can pass through the blood-brain barrier (BBB).
Catalog No. T6845Cas No. 1394076-92-6
Select Batch
Purity:99.42%
Contact us for more batch information

Resource Download

GNE-317

Catalog No. T6845Cas No. 1394076-92-6

GNE-317, a PI3K/mTOR inhibitor, can pass through the blood-brain barrier (BBB).
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
1 mg$33In Stock
2 mg$47In Stock
5 mg$76In Stock
10 mg$122In Stock
25 mg$222In Stock
50 mg$368In Stock
100 mg$456In Stock
200 mg$668In Stock
1 mL x 10 mM (in DMSO)$84In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "GNE-317"

Product Introduction

Bioactivity
Description
GNE-317, a PI3K/mTOR inhibitor, can pass through the blood-brain barrier (BBB).
In vitro
GNE-317, an oxetane derivative synthesized by GDC-0980, is aimed at reducing substrate affinity for efflux transporters. In vitro, GDC-0980 demonstrate similar profiles with GNE-317 in MTS cytotoxicity experiments using the GL261 cell line.
In vivo
Mice, which are i.c. inoculation with GL261-GFP-Luc cells Seven days later,are treated once daily with the maximum tolerated dose of GDC-0980 (7.5 mg/kg), GNE-317 (30 mg/kg), or vehicle. Tumor growth is tracked in GL261 through bioluminescence imaging on a weekly basis. There are no significant differences in GL261 tumor growth among the 3 groups treated by GDC-0980, GNE-317 or vehicle. The data show that the drugs have limited efficacy in inducing cell death in the GL261 cell line. Although GNE-317 has greater delivery and enhanced therapeutic targeting efficacy, it is not effective in the treatment of the GL261 tumor.
Cell Research
Cellular viability assays are set up in a 96-well format with 2000 GL261-GFP-Luc cells plated per well in the culture conditions. GL261, an aggressive C57BL/6J-derived glioma line, is transfected with both green fluorescent protein (GFP) and luciferase (Luc) from separate plasmids.GL261-GFP-Luc cells are cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS and Penicillin/Streptomycin (100 U/mL) at 5% oxygen, and are selected by 4 mg/mL Puromycin and 4 mg/mL G418. Suspend GNE-317 in DMSO and then diluted with the medium.GL261-GFP-Luc cells are incubated in the presence of drug or vehicle for 48 hours, and viability was assessed by MTS assay. Results were detected using a Synergy Mx automated plate reader,which are set up absorbance at 490 nm and used to determine viability and at 650 nm to account for the background. Numerical values from drug-treated wells are normalized to the values of vehicle-treated wells to yield percent survival.
Animal Research
7-week-old C57BL/6J mice are implanted GL261-GFP-Luc cells. When tumors reach 5e7 photons/s/cm2/sr (radiance), mice are orally administered the maximum tolerated the dose,which is defined as <10% drop in mice bodyweight dose, GDC-0980 for 7.5 mg/kg, GNE-317 for 30 mg/kg or vehicle once daily for 3 days. At 1 or 6 hours after the third dose, mice are euthanized with carbon dioxide and perfused with 30 mL PBS.
AliasGNE317
Chemical Properties
Molecular Weight414.48
FormulaC19H22N6O3S
Cas No.1394076-92-6
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 12.5 mg/mL (30.16 mM)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.4127 mL12.0633 mL24.1266 mL120.6331 mL
5 mM0.4825 mL2.4127 mL4.8253 mL24.1266 mL
10 mM0.2413 mL1.2063 mL2.4127 mL12.0633 mL
20 mM0.1206 mL0.6032 mL1.2063 mL6.0317 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy GNE-317 | purchase GNE-317 | GNE-317 cost | order GNE-317 | GNE-317 chemical structure | GNE-317 in vivo | GNE-317 in vitro | GNE-317 formula | GNE-317 molecular weight